Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
6 days ago · Get the latest multiple sclerosis news, patient views, and caregiver perspectives from one of the largest MS communities online.
Top 10 MS stories of 2023 - Multiple Sclerosis News Today
News; Top 10 MS stories of 2023 Top 10 MS stories of 2023. Of most interest to readers was news on potential treatments, triggers. by Marisa Wexler, MS | January 2, 2024.
1-year fenebrutinib inhibits nearly all MS signs in relapsing MS trial
Sep 6, 2024 · The Phase 2 FENopta trial (NCT05119569) evaluated fenebrutinib’s safety and efficacy in 109 adults, ages 18-55, with relapsing forms of MS, including relapsing-remitting …
The MS News Today Podcast - Multiple Sclerosis News Today
After 24 years with the National MS Society, most recently as Chief Advocacy, Services and Science Officer, Dr. Tim Coetzee is the new President and CEO of the Society.
MS news notes: Vaccines, migraines, eye-tracking technology
Sep 18, 2023 · The MS News Today story “No greater risk of hospitalization found after vaccines in MS in study” reports on a nationwide study in France involving over 100,000 people, that …
MRI analysis of MS ReBUILD data shows remyelination with...
Jun 16, 2023 · October 8, 2024 News by Esteban Domínguez Cerezo, MS. Nerve stimulator for myelin repair to enter RRMS clinical trial. March 6, 2024 News by Marisa Wexler, MS.
MS news notes: Stem cell therapy, early Aubagio use, DMTs
May 1, 2023 · Stem cell therapy receives a good report card. The MS News Today article “AAN 2023: Low rates of disease activity after stem cell transplant” reports on a follow-up study of 22 …
MS news notes: Vumerity, herpes virus, caregivers
Nov 27, 2023 · Final results are in from the EVOLVE-MS-1 clinical trial for patients with relapsing-remitting MS (RRMS) who were treated with Vumerity (diroximel fumarate), and the news is …
MS news notes: Stem cell therapy, genetic variant, diet
Jul 3, 2023 · The MS News Today article “Stem cell therapy highly effective in active RRMS: Real-world study” reports that nearly 80% of participants with highly active relapsing-remitting …
MS News Notes: ECTRIMS, Ocrevus, Kesimpta, Epstein-Barr, DMTs
Oct 31, 2022 · The MS News Today story titled “#ECTRIMS2022 – 2-year Ocrevus Effective for Early MS Patients: Data” reports that if treatment with Ocrevus is started in the earliest stages …